
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company that leverages its eXplainable Artificial Intelligence (eXp.Al) technology to redefine clinical trial design and analysis. By focusing on precision and innovation, Ariana aims to maximize the impact of clinical trials, increasing the chances of success for therapeutics. Their platform moves beyond binary readouts to capture the value of clinical assets and guide them toward approval. The company integrates clinical data with omics, immunological readouts, microbiota, patient-reported outcomes, and real-world evidence. Ariana Pharma has a track record in therapeutic areas like cancer, neurodegenerative diseases, and metabolic disorders, and is based in Paris, France, with a US subsidiary.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company that leverages its eXplainable Artificial Intelligence (eXp.Al) technology to redefine clinical trial design and analysis. By focusing on precision and innovation, Ariana aims to maximize the impact of clinical trials, increasing the chances of success for therapeutics. Their platform moves beyond binary readouts to capture the value of clinical assets and guide them toward approval. The company integrates clinical data with omics, immunological readouts, microbiota, patient-reported outcomes, and real-world evidence. Ariana Pharma has a track record in therapeutic areas like cancer, neurodegenerative diseases, and metabolic disorders, and is based in Paris, France, with a US subsidiary.
Founded: 2003 (Institut Pasteur spin-off)
Headquarters: Paris, France (US subsidiary in Cambridge, MA)
Product: KEM® explainable AI platform for biomarker discovery and clinical trial design
Therapeutic focus: Oncology, immunotherapy, neurodegenerative and metabolic disorders
Funding signal: Series A led by Vizille Capital Innovation (Jul 2008)
Improving clinical trial design and analysis through explainable AI and biomarker-driven patient selection.
2003
Biotechnology
“Series A led by Vizille Capital Innovation”